DaVita’s recession-resistant business is growing internationally, but shares continue to trade at a heavily discounted valuation.
Merck could be in for a major move if the pharma can soften the blow of an upcoming patent expiration.
Universal Health Services is undervalued and under the radar, trading at a big discount to peers despite promising growth prospects.
10 stocks we like better than DaVita ›
As more uncertainty hits the stock market, defensive sectors like healthcare are starting to look attractive once again. Healthcare stocks are a wide universe, with over 1,100 listed on major U.S. exchanges.
Many healthcare investors focus on faster-growing companies, or those in faster-growing segments of the sector, but it’s a great place to find undervalued gems as well. Although plenty of stocks in this category are cheap for a reason, and are at risk of becoming value traps, there are a few where the market has overreacted, creating an ideal situation for contrarian investors.
That’s the situation with the following three undervalued healthcare stocks.
So far this year, shares in dialysis center operator DaVita (NYSE: DVA) have slumped, falling by around 14% since January. A variety of factors have put pressure on the stock.
These have included disappointing quarterly earnings releases, a ransomware attack, and reports on Warren Buffett’s Berkshire Hathaway, a longtime DaVita shareholder, trimming its position.
However, while all of this gives DaVita some serious value-trap vibes, there are silver linings to these perceived negatives. Berkshire’s steady selling has to do with a shareholder agreement in which it sells shares back to DaVita when its ownership percentage exceeds 45%. This happens often because DaVita continues to aggressively repurchase shares.
Regarding earnings, DaVita is expanding internationally. This growth, coupled with the stability of its U.S.-based core business, could mean more well-received quarterly earnings releases in the future. The stock, trading at a forward price-to-earnings ratio (P/E) of 11, could experience valuation expansion as well.
Merck (NYSE: MRK) has yet to release a blockbuster drug for weight loss, but the pharmaceutical giant continues to report strong earnings, namely from its cancer drug Keytruda. The issue, however, is that the drug’s patent protection expires in 2028.
When that happens, the release of generic biosimilars will likely lead to a severe reduction in Keytruda sales. So it’s not surprising you can buy this stock today for just 9 times forward earnings. However, Merck could find a solution to this big problem.
